In short. A biologic prepared at the point of care, sitting in a space where the product approval framework does not apply at all.
Key points
- A machine cleared to separate blood has been assessed for separating blood.
- The claim that the resulting preparation improves skin, restores volume or rebuilds tissue has not been assessed by anybody, and a description that runs the two together is borrowing a clearance for something it does not cover.
This treatment sits in a regulatory space that exists because the material is made at the point of care rather than supplied as a product. Understanding the shape of that space explains both the freedom and the uncertainty attached to it.
No product, no authorisation
An injectable that is manufactured is authorised as a product: its composition is defined, its manufacture is inspected, its safety and performance are assessed for a named indication, and its labelling states what it is for. None of that structure can attach to a preparation made from one person’s blood minutes before it is injected into that person. There is no batch, no release specification and no product to authorise, so there is no approved indication and no labelling to read.
The devices are regulated, and for something else
A centrifuge and the tubes used with it are regulated as laboratory equipment. Their authorisation covers separating blood reliably and safely, which is a technical task rather than a clinical one. The gap that follows is precise: the equipment is assessed for what it does mechanically, and no authority has assessed the claim that what it produces is a useful aesthetic treatment. Both statements are true at once, and the second is routinely inferred from the first.
Approval of the equipment is not approval of the treatment
A machine cleared to separate blood has been assessed for separating blood. The claim that the resulting preparation improves skin, restores volume or rebuilds tissue has not been assessed by anybody, and a description that runs the two together is borrowing a clearance for something it does not cover.
Rules differ between jurisdictions
Blood-derived treatments are not governed uniformly. Some jurisdictions regulate the preparation and administration of blood components for clinical use; others treat a same-session autologous preparation differently from a manufactured product; and several have issued guidance about how such treatments may be described in advertising. Because the rules differ, a statement that a treatment is permitted somewhere is not a statement about what it has been shown to do, and it may not even be a statement about where you are reading it.
What follows for a person considering it
That the questions worth asking are about the process rather than the product, because there is no product. That a claim of approval should be followed by a question about what exactly was approved, since the preparation itself generally is not. And that the absence of a regulatory standard is a reason to rely on the clinic’s own description of what it does, which makes that description worth asking for.
Three questions about a regulatory claim
- What exactly is approved here — the device, the protocol, or the treatment?
- Is the material prepared and used in the same session, or supplied from elsewhere?
- Who is responsible for the preparation, and what standard is it held to?
None of this argues that the treatment is improper. It establishes what kind of oversight applies, which is the background against which everything else on this site should be read.
Frequently asked questions
Is PRF approved as a treatment?
No. There is no product authorisation and no approved indication, because there is no manufactured product to authorise. What is injected is prepared in the room from the patient's own blood and used in the same session, which places it outside the framework that governs manufactured injectables.
Are the devices regulated?
The centrifuge and the tubes are regulated as laboratory equipment, and that authorisation covers separating blood rather than producing a treatment. That is the gap: the equipment is assessed for a technical task, and no authority has assessed the clinical claim attached to what comes out of it.
Does the absence of approval make it unsafe?
No. It means nobody has been required to demonstrate that it works before offering it, and it means the composition of what is injected is not defined by an external standard. Absence of approval is not evidence of harm and it is also not evidence of anything else.
Risks & Limitations
- The preparation is made in the room and is not standardised, so two clinics offering the same named treatment are not necessarily offering the same material.
- Blood handled outside a controlled laboratory is a medium in which bacteria grow, so preparation carries a risk of infection that the source of the blood does not remove.
- The material is reabsorbed over a short period, so it does not restore volume the way a filler does.
- There is no product authorisation and no approved indication, because there is no manufactured product to authorise.
- Growth factors measured in laboratory work are a finding about the material and not a demonstrated clinical result.
When to Seek Care
- Redness, warmth, swelling or pain that is increasing rather than settling after an injection.
- Discharge from an injection site, or a fever — seek prompt clinical assessment.
- An uneven or lumpy result, or any change in the treated area that concerns you.
- Contact the service that performed the treatment, or the hospital’s outpatient channels, rather than relying on a website.
References & Further Reading
- U.S. Food and Drug Administration (FDA) — guidance on autologous cellular products and point-of-care preparation
- European Medicines Agency (EMA) and national regulators — guidance on blood-derived and autologous treatments
- National Medical Products Administration (NMPA, China) — regulation of blood-derived preparations and devices
- World Health Organization (WHO) — guidance on the safe preparation and handling of blood components
- Cochrane Library — systematic reviews of platelet concentrates for skin and wound indications
This page is patient education, not medical advice, and it does not cite individual studies. It reviews evidence and regulation; it is not a booking page and does not recommend a treatment. Discuss your own case with a qualified clinician. To ask a question about this review, see Contact & Consultation.